Jun Wang

InstitutionThe University of Arizona
AddressTucson
Arizona
United States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 10 Covid-19 publications, with a maximum of 2 publications in June 2021
    All Publications
    Bar chart showing 76 publications over 13 distinct years, with a maximum of 15 publications in 2017
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hu Y, Meng X, Zhang F, Xiang Y, Wang J. The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor. Emerg Microbes Infect. 2021 Dec; 10(1):317-330. PMID: 33560940.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    2. Ma C, Sacco MD, Xia Z, Lambrinidis G, Townsend JA, Hu Y, Meng X, Szeto T, Ba M, Zhang X, Gongora M, Zhang F, Marty MT, Xiang Y, Kolocouris A, Chen Y, Wang J. Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay. ACS Cent Sci. 2021 Jul 28; 7(7):1245-1260. PMID: 34341772.
      Citations: 3     
    3. Xia Z, Sacco M, Hu Y, Ma C, Meng X, Zhang F, Szeto T, Xiang Y, Chen Y, Wang J. Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir. ACS Pharmacol Transl Sci. 2021 Aug 13; 4(4):1408-1421. PMID: 34414360.
      Citations: 3     
    4. Cáceres CJ, Cardenas-Garcia S, Carnaccini S, Seibert B, Rajao DS, Wang J, Perez DR. Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. Sci Rep. 2021 05 05; 11(1):9609. PMID: 33953295.
      Citations: 9     Fields:    Translation:AnimalsCells
    5. Kitamura N, Sacco MD, Ma C, Hu Y, Townsend JA, Meng X, Zhang F, Zhang X, Ba M, Szeto T, Kukuljac A, Marty MT, Schultz D, Cherry S, Xiang Y, Chen Y, Wang J. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors. J Med Chem. 2022 02 24; 65(4):2848-2865. PMID: 33891389.
      Citations: 9     Fields:    
    6. Hu Y, Ma C, Szeto T, Hurst B, Tarbet B, Wang J. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses. ACS Infect Dis. 2021 03 12; 7(3):586-597. PMID: 33645977.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    7. Ma C, Wang J. Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors. Proc Natl Acad Sci U S A. 2021 02 23; 118(8). PMID: 33568498.
      Citations: 13     Fields:    Translation:Humans
    8. Sacco MD, Ma C, Lagarias P, Gao A, Townsend JA, Meng X, Dube P, Zhang X, Hu Y, Kitamura N, Hurst B, Tarbet B, Marty MT, Kolocouris A, Xiang Y, Chen Y, Wang J. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L. Sci Adv. 2020 12; 6(50). PMID: 33158912.
      Citations: 63     Fields:    Translation:HumansAnimalsCells
    9. Tzitzoglaki C, McGuire K, Lagarias P, Konstantinidi A, Hoffmann A, Fokina NA, Ma C, Papanastasiou IP, Schreiner PR, Vázquez S, Schmidtke M, Wang J, Busath DD, Kolocouris A. Chemical Probes for Blocking of Influenza A M2 Wild-type and S31N Channels. ACS Chem Biol. 2020 09 18; 15(9):2331-2337. PMID: 32786258.
      Citations: 3     Fields:    Translation:HumansCellsPHPublic Health
    10. Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y, Szeto T, Zhang X, Tarbet B, Marty MT, Chen Y, Wang J. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020 08; 30(8):678-692. PMID: 32541865.
      Citations: 179     Fields:    Translation:HumansAnimalsCellsPHPublic Health